Long-Term Survival due to Chemotherapy including Paclitaxel in a Patient with Metastatic Primary Splenic Angiosarcoma

A primary splenic angiosarcoma is a rare type of soft tissue sarcoma and is associated with an extremely poor prognosis. In this study, we describe the case of a patient who was diagnosed with metastatic primary splenic angiosarcoma and survived for about 2 years. A 62-year-old female was referred t...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Masanori Takehara, Hiroshi Miyamoto, Yasuteru Fujino, Tetsu Tomonari, Tatsuya Taniguchi, Shinji Kitamura, Koichi Okamoto, Masahiro Sogabe, Yasushi Sato, Naoki Muguruma, Yoshimi Bando, Tetsuji Takayama
Formato:	article
Lenguaje:	EN
Publicado:	Karger Publishers 2021
Materias:	angiosarcoma hepatic metastasis bone metastasis paclitaxel chemotherapy Diseases of the digestive system. Gastroenterology RC799-869
Acceso en línea:	https://doaj.org/article/03698ea5c4174274bdea0faf794791ee
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:03698ea5c4174274bdea0faf794791ee
record_format	dspace
spelling	oai:doaj.org-article:03698ea5c4174274bdea0faf794791ee2021-11-11T10:40:44ZLong-Term Survival due to Chemotherapy including Paclitaxel in a Patient with Metastatic Primary Splenic Angiosarcoma1662-063110.1159/000519211https://doaj.org/article/03698ea5c4174274bdea0faf794791ee2021-10-01T00:00:00Zhttps://www.karger.com/Article/FullText/519211https://doaj.org/toc/1662-0631A primary splenic angiosarcoma is a rare type of soft tissue sarcoma and is associated with an extremely poor prognosis. In this study, we describe the case of a patient who was diagnosed with metastatic primary splenic angiosarcoma and survived for about 2 years. A 62-year-old female was referred to us for the treatment of splenic angiosarcoma with disseminated intravascular coagulation (DIC) and multiple liver and bone metastases. Paclitaxel therapy resulted in recovery from DIC and enabled her to continue sequential treatment through to sixth-line chemotherapy. We reviewed all splenic angiosarcoma case reports which were described as stage IV to date and compared with our case. From these data, we found that the median overall survival was 105 days, and the prognosis of splenic angiosarcoma of stage IV was worse than conventional case series. Splenectomy was performed in more patients than chemotherapy as a treatment. Moreover, various chemotherapeutic regimens were used. These data suggest that administering chemotherapy including paclitaxel to patients with splenic angiosarcoma might improve their prognosis.Masanori TakeharaHiroshi MiyamotoYasuteru FujinoTetsu TomonariTatsuya TaniguchiShinji KitamuraKoichi OkamotoMasahiro SogabeYasushi SatoNaoki MugurumaYoshimi BandoTetsuji TakayamaKarger Publishersarticleangiosarcomahepatic metastasisbone metastasispaclitaxelchemotherapyDiseases of the digestive system. GastroenterologyRC799-869ENCase Reports in Gastroenterology, Vol 15, Iss 3, Pp 910-918 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	angiosarcoma hepatic metastasis bone metastasis paclitaxel chemotherapy Diseases of the digestive system. Gastroenterology RC799-869
spellingShingle	angiosarcoma hepatic metastasis bone metastasis paclitaxel chemotherapy Diseases of the digestive system. Gastroenterology RC799-869 Masanori Takehara Hiroshi Miyamoto Yasuteru Fujino Tetsu Tomonari Tatsuya Taniguchi Shinji Kitamura Koichi Okamoto Masahiro Sogabe Yasushi Sato Naoki Muguruma Yoshimi Bando Tetsuji Takayama Long-Term Survival due to Chemotherapy including Paclitaxel in a Patient with Metastatic Primary Splenic Angiosarcoma
description	A primary splenic angiosarcoma is a rare type of soft tissue sarcoma and is associated with an extremely poor prognosis. In this study, we describe the case of a patient who was diagnosed with metastatic primary splenic angiosarcoma and survived for about 2 years. A 62-year-old female was referred to us for the treatment of splenic angiosarcoma with disseminated intravascular coagulation (DIC) and multiple liver and bone metastases. Paclitaxel therapy resulted in recovery from DIC and enabled her to continue sequential treatment through to sixth-line chemotherapy. We reviewed all splenic angiosarcoma case reports which were described as stage IV to date and compared with our case. From these data, we found that the median overall survival was 105 days, and the prognosis of splenic angiosarcoma of stage IV was worse than conventional case series. Splenectomy was performed in more patients than chemotherapy as a treatment. Moreover, various chemotherapeutic regimens were used. These data suggest that administering chemotherapy including paclitaxel to patients with splenic angiosarcoma might improve their prognosis.
format	article
author	Masanori Takehara Hiroshi Miyamoto Yasuteru Fujino Tetsu Tomonari Tatsuya Taniguchi Shinji Kitamura Koichi Okamoto Masahiro Sogabe Yasushi Sato Naoki Muguruma Yoshimi Bando Tetsuji Takayama
author_facet	Masanori Takehara Hiroshi Miyamoto Yasuteru Fujino Tetsu Tomonari Tatsuya Taniguchi Shinji Kitamura Koichi Okamoto Masahiro Sogabe Yasushi Sato Naoki Muguruma Yoshimi Bando Tetsuji Takayama
author_sort	Masanori Takehara
title	Long-Term Survival due to Chemotherapy including Paclitaxel in a Patient with Metastatic Primary Splenic Angiosarcoma
title_short	Long-Term Survival due to Chemotherapy including Paclitaxel in a Patient with Metastatic Primary Splenic Angiosarcoma
title_full	Long-Term Survival due to Chemotherapy including Paclitaxel in a Patient with Metastatic Primary Splenic Angiosarcoma
title_fullStr	Long-Term Survival due to Chemotherapy including Paclitaxel in a Patient with Metastatic Primary Splenic Angiosarcoma
title_full_unstemmed	Long-Term Survival due to Chemotherapy including Paclitaxel in a Patient with Metastatic Primary Splenic Angiosarcoma
title_sort	long-term survival due to chemotherapy including paclitaxel in a patient with metastatic primary splenic angiosarcoma
publisher	Karger Publishers
publishDate	2021
url	https://doaj.org/article/03698ea5c4174274bdea0faf794791ee
work_keys_str_mv	AT masanoritakehara longtermsurvivalduetochemotherapyincludingpaclitaxelinapatientwithmetastaticprimarysplenicangiosarcoma AT hiroshimiyamoto longtermsurvivalduetochemotherapyincludingpaclitaxelinapatientwithmetastaticprimarysplenicangiosarcoma AT yasuterufujino longtermsurvivalduetochemotherapyincludingpaclitaxelinapatientwithmetastaticprimarysplenicangiosarcoma AT tetsutomonari longtermsurvivalduetochemotherapyincludingpaclitaxelinapatientwithmetastaticprimarysplenicangiosarcoma AT tatsuyataniguchi longtermsurvivalduetochemotherapyincludingpaclitaxelinapatientwithmetastaticprimarysplenicangiosarcoma AT shinjikitamura longtermsurvivalduetochemotherapyincludingpaclitaxelinapatientwithmetastaticprimarysplenicangiosarcoma AT koichiokamoto longtermsurvivalduetochemotherapyincludingpaclitaxelinapatientwithmetastaticprimarysplenicangiosarcoma AT masahirosogabe longtermsurvivalduetochemotherapyincludingpaclitaxelinapatientwithmetastaticprimarysplenicangiosarcoma AT yasushisato longtermsurvivalduetochemotherapyincludingpaclitaxelinapatientwithmetastaticprimarysplenicangiosarcoma AT naokimuguruma longtermsurvivalduetochemotherapyincludingpaclitaxelinapatientwithmetastaticprimarysplenicangiosarcoma AT yoshimibando longtermsurvivalduetochemotherapyincludingpaclitaxelinapatientwithmetastaticprimarysplenicangiosarcoma AT tetsujitakayama longtermsurvivalduetochemotherapyincludingpaclitaxelinapatientwithmetastaticprimarysplenicangiosarcoma
_version_	1718439097712771072

Long-Term Survival due to Chemotherapy including Paclitaxel in a Patient with Metastatic Primary Splenic Angiosarcoma

Ejemplares similares